Fulcrum Therapeutics/$FULC
1D1W1MYTD1Y5YMAX
Capital at risk
About Fulcrum Therapeutics
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.
- Ticker
- $FULC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 9
- Headquarters
- Cambridge, United States
- Website
- www.fulcrumtx.com
FULC Metrics
BasicAdvanced
$290M
-
-$1.21
2.58
-
Price and volume
Market cap
$290M
Beta
2.58
52-week high
$15.74
52-week low
$2.83
Average daily volume
1.7M
Financial strength
Current ratio
31.351
Quick ratio
31.158
Long term debt to equity
0.888
Total debt to equity
1.699
Profitability
EBITDA (TTM)
-85.396
Management effectiveness
Return on assets (TTM)
-19.59%
Return on equity (TTM)
-32.38%
Valuation
Price to book
0.93
Price to tangible book (TTM)
0.93
Price to free cash flow (TTM)
-4.034
Free cash flow yield (TTM)
-24.79%
Free cash flow per share (TTM)
-0.942
Growth
Earnings per share change (TTM)
2.65%
3-year earnings per share growth (CAGR)
-12.24%
What the Analysts think about FULC
Analyst ratings (Buy, Hold, Sell) for Fulcrum Therapeutics stock.
Analyst projections of the future price of Fulcrum Therapeutics stock.
FULC Financial Performance
Revenues and expenses
FULC Earnings Performance
Company profitability
Upcoming events
No upcoming events
FULC News
AllArticlesVideos
Kaplan Fox Urges Investors of Fulcrum Therapeutics, Inc. (FULC) with Losses to Contact the Firm
Newsfile Corp3 days ago
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (FULC) of an Ongoing Securities Investigation
Newsfile Corp4 days ago
FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire1 week ago
Funds containing FULC
AllUSDGBPEUR
Fund name | Fund size | $FULC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.02% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.